Roche Called the U.S. Government's Drug Pricing Tactics 'Cold-Blooded Blackmail'
Roche's chairman called U.S. drug pricing tactics "cold-blooded blackmail" at a Swiss forum, comparing tariff threats to having a gun pointed at the company. The escalating war of words between one of the world's biggest drugmakers and Washington is reshaping how pharma fights back on pricing.
Imagine someone walks up to you, points a gun at your head, and says: sign this contract or else.
That's essentially how Roche's chairman, Severin Schwan, described the company's position amid U.S. tariff-linked drug price negotiations. In a TV interview in Interlaken, Schwan didn't mince words. He called Washington's approach "cold-blooded blackmail" and "the law of the strongest." His analogy was blunt: if you don't sign, there will be 200% tariffs tomorrow.
It's the kind of language you almost never hear from the head of one of the world's largest drugmakers. And it tells you everything about where the pharma-government relationship stands right now.
The Deal That Started It All
To understand why Schwan is this angry, you have to rewind to December 2025. That's when Roche, through its U.S. arm Genentech, signed an agreement with the U.S. government to lower prices on certain medicines for Americans, particularly in Medicaid. Novartis and other big pharma companies signed similar deals around the same time.
In return, Roche got a three-year reprieve from threatened tariffs on pharmaceutical imports. Those tariffs? As high as 200%. The whole arrangement was part of the Trump administration's broader push to bring U.S. drug prices in line with what other wealthy countries pay, using a "Most Favored Nation" pricing framework.
On paper, it looks like a negotiation. Both sides gave something. Both sides got something. But Schwan's argument is that when the alternative is a 200% tariff that would cripple your business overnight, calling it a "voluntary agreement" is a stretch. It's like saying someone "voluntarily" handed over their wallet because the mugger asked politely first.
Why Roche Is Playing Along (for Now)
Despite the fiery rhetoric from the chairman's podium, Roche's CEO Thomas Schinecker has taken a more pragmatic tone. He's confirmed that Roche is in continuous talks with Washington on pricing reforms and has acknowledged that U.S. drug prices "will be lowered" under the new agreements. That reality is already baked into Roche's financial planning.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Schinecker has even found a silver lining in the chaos. He's argued that about 50% of profits in the U.S. drug supply chain flow to intermediaries like pharmacy benefit managers (PBMs), the middlemen who negotiate between drugmakers and insurers. His pitch to Washington: if you let us sell directly to patients and cut out PBMs, it would be "very easy" to slash list prices by half.
It's a clever bit of corporate judo. Instead of just fighting the price cuts, Roche is trying to redirect the conversation toward the supply chain's bloated middle. If the government wants lower prices, Roche is saying, let's take it out of the middlemen's margins instead of the R&D budget.
The Collateral Damage Nobody's Talking About
But the pricing pressure is already having real consequences for patients who don't exist yet. Schinecker has said Roche abandoned some clinical trials and potential deals because the math no longer works under the new pricing landscape. When you cut the revenue a drug can generate over its lifetime, some programs that were borderline suddenly fall below the line.
Think of it like renovating a house. If someone tells you the home's value just dropped 30%, you're probably not going to spring for the marble countertops. Roche is making similar calculations across its pipeline, quietly shelving projects that can't justify their costs in a world of lower U.S. prices.
And the ripple effects go global. Schinecker has warned that lowering U.S. prices under the new GDP-based framework will likely raise future drug prices in wealthier countries like Switzerland. The logic works like this: if the U.S. uses GDP per capita to benchmark what it pays, countries richer than America (on a per-capita basis) would be expected to pay more. It's a pricing seesaw, and Europe might be on the wrong end of it.
Tariffs Are Getting Worse, Not Better
The April 2026 White House proclamation added another layer of complexity. The administration imposed 100% duties on patented pharmaceuticals and related ingredients, with a lower 20% rate for companies that have approved U.S. manufacturing plans. Those tariffs start hitting some companies on July 31, 2026, and others by September 29.
Roche says its late-2025 deal should keep its medicines exempt from this round. But its diagnostics business (Roche is also one of the world's biggest diagnostics companies) may still face duties after an initial grace period. And there's the lingering question of whether a three-year reprieve is really three years when the rules keep changing.
Remember, Roche had previously flagged $50 billion in planned U.S. investments that it warned could be jeopardized by aggressive pricing orders. That's not a small number. It's the kind of figure that gets congressional attention, which may be exactly why Roche keeps bringing it up.
The Bigger Picture: Pharma vs. Washington, Round Three
Roche isn't the only company frustrated. The IRA's Medicare negotiation program, which sets prices for high-spending drugs, has already weathered multiple legal challenges from the likes of Merck, Bristol Myers Squibb, AstraZeneca, and others. Merck notably described the process as "extortion" rather than negotiation. So far, none of those lawsuits have succeeded; courts have largely sided with the government.
Interestingly, Roche has stayed on the sidelines of the IRA litigation. Schinecker has said the company isn't leading legal challenges because other drugmakers are more directly affected. None of Roche's drugs appeared on the first 10 selected for Medicare price negotiation in 2026, and none have been publicly identified on the 15-drug list for the 2027 cycle either. Roche's real exposure likely comes in 2028 and beyond, when the program expands to cover Part B drugs (the physician-administered, often infused medications that make up a big chunk of Roche's oncology portfolio).
But by picking the "blackmail" fight on the tariff front instead of the courtroom front, Roche is playing a different game. It's a PR strategy as much as a business one: frame the U.S. government as the aggressor, position Roche as the reasonable party willing to lower prices if Washington plays fair, and keep the public conversation focused on PBMs and middlemen rather than manufacturer profits.
What Happens Next
The tension between pharma and Washington isn't going away. If anything, Schwan's comments signal that the industry's patience with "negotiate or else" tactics is wearing thin. The question is whether words like "blackmail" remain rhetorical grenades lobbed from Swiss conference stages, or whether they translate into real changes in how companies engage with U.S. policy.
For Roche specifically, the next few months are critical. July and September 2026 tariff deadlines are approaching. Direct-to-consumer pricing models are still in discussion. And somewhere in Basel, a team of executives is running spreadsheets on which pipeline programs still make financial sense.
The drug pricing war has a new front. And Roche just made sure everyone knows which side it's on.
5 min read
The First Chinese Anesthetic to Crack the FDA
A Chinese pharma company just got FDA approval for a novel anesthetic that could chip away at propofol's 35-year reign. It's the first China-originated IV anesthetic to crack the U.S. market, and the implications go way beyond the operating room.
